

Petr Novak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8364614/publications.pdf>

Version: 2024-02-01

8
papers

677
citations

1478505

6
h-index

1872680

6
g-index

8
all docs

8
docs citations

8
times ranked

813
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial. <i>Lancet Neurology</i> , The, 2017, 16, 123-134.	10.2	233
2	First-in-man tau vaccine targeting structural determinants essential for pathological tau- τ interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 44.	6.2	193
3	FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 108.	6.2	87
4	Ten Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads Ahead. <i>Frontiers in Neuroscience</i> , 2018, 12, 798.	2.8	67
5	ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease. <i>Nature Aging</i> , 2021, 1, 521-534.	11.6	64
6	Tau Conformation as a Target for Disease-Modifying Therapy: The Role of Truncation. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S535-S546.	2.6	29
7	Nanobiotechnology in Neurodegenerative Diseases. , 2019, , 65-138.		4
8	O4-08-01: Characterisation of the Antibody Response to AADVAC1: The First-in-Kind Active Vaccine Against Neurofibrillary TAU Pathology. , 2016, 12, P351-P351.		0